Measurable residual disease for secondary acute myeloid leukemia prior to allogeneic hematopoietic cell transplantation: does it make a difference?
Bone Marrow Transplant
.
2022 Oct;57(10):1473-1474.
doi: 10.1038/s41409-022-01765-9.
Epub 2022 Jul 28.
Authors
Firas El Chaer
1
,
Karen K Ballen
2
Affiliations
1
Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA.
2
Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA. KB3TC@hscmail.mcc.virginia.edu.
PMID:
35902643
DOI:
10.1038/s41409-022-01765-9
No abstract available
Publication types
Editorial
MeSH terms
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myeloid, Acute* / complications
Leukemia, Myeloid, Acute* / therapy
Neoplasm, Residual
Transplantation Conditioning